CHICAGO--For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

PRP contains growth factors that promote cell proliferation and is prepared from the patient's own blood tissue. It has received popular attention recently because of its use in treating sports injuries in professional athletes, but the jury is still out on whether it is effective.

"There have been few controlled clinical trials, and results are inconsistent, but data so far suggests that it could be a promising treatment for healing in a variety of tissues," said Dr. Brian Cole, orthopedic surgeon and head of the cartilage restoration center at Rush. "The therapy will not be a cure for osteoarthritis, but it could help put off the day when a patient will need to get a knee implant." Cole is professor of orthopedic surgery at Rush University and head team physician for the Chicago Bulls.
At present, the standard of care is either corticosteroid injections, which may provide relief for about three months, or synthetic lubricants containing hyaluronic acid, which can last for up to a year.

In the double-blind, randomized, controlled study, 100 patients will receive either hyaluronic acid or PRP. The PRP is prepared from 10 millimeters of the patient's own blood. The blood is spun in a centrifuge to separate the platelets from the red and white blood cells. The platelets are then injected into the knee joint using ultrasound imaging to guide placement.

Patients will receive three injections over three weeks and will be monitored for two years. In periodic clinical exams, the physician will assess pain and knee function. In addition, a teaspoon-size sample will be taken of the synovial fluid around the knee joint to test for molecular changes that may indicate a shift in the balance of anabolic factors that increase the buildup of tissue and catabolic factors that break it down. An imbalance in these factors has been implicated in the deterioration of cartilage that leads to osteoarthritis.

Rush is a not-for-profit academic medical center comprising Rush University Medical Center, Rush University, Rush Oak Park Hospital and Rush Health.

Rush is currently constructing a 14-floor, 806,000-square-foot hospital building near the corner of Ashland Avenue and the Eisenhower Expressway. The new hospital, scheduled to open in 2012, is the centerpiece of a $1 billion, ten-year campus redevelopment plan called the Rush Transformation, which also includes completion of a new orthopedics building, a new parking garage and central power plant, renovations of selected existing buildings and demolition of obsolete buildings. In January, Rush opened the new Rush University Cancer Center in completely renovated facilities in its Professional Buildings. The new hospital is designed and built to conserve energy and water, reduce waste and use sustainable building materials. Rush is seeking Leadership in Energy and Environmental Design (LEED) gold certification from the U.S. Green Building Council. It will be the first full-service, "green" hospital in Chicago.

Rush's mission is to provide the best possible care for its patients. Educating tomorrow's health care professional, researching new and more advanced treatment options, transforming its facilities and investing in new technologies-all are undertaken with the drive to improve patient care now, and for the future.

More HCB News